Literature DB >> 24121277

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

M Venere1, P Hamerlik2, Q Wu1, R D Rasmussen3, L A Song1, A Vasanji4, N Tenley4, W A Flavahan1, A B Hjelmeland5, J Bartek2, J N Rich5.   

Abstract

Glioblastoma-initiating cells (GICs) are self-renewing tumorigenic sub-populations, contributing to therapeutic resistance via decreased sensitivity to ionizing radiation (IR). GIC survival following IR is attributed to an augmented response to genotoxic stress. We now report that GICs are primed to handle additional stress due to basal activation of single-strand break repair (SSBR), the main DNA damage response pathway activated by reactive oxygen species (ROS), compared with non-GICs. ROS levels were higher in GICs and likely contributed to the oxidative base damage and single-strand DNA breaks found elevated in GICs. To tolerate constitutive DNA damage, GICs exhibited a reliance on the key SSBR mediator, poly-ADP-ribose polymerase (PARP), with decreased viability seen upon small molecule inhibition to PARP. PARP inhibition (PARPi) sensitized GICs to radiation and inhibited growth, self-renewal, and DNA damage repair. In vivo treatment with PARPi and radiotherapy attenuated radiation-induced enrichment of GICs and inhibited the central cancer stem cell phenotype of tumor initiation. These results indicate that elevated PARP activation within GICs permits exploitation of this dependence, potently augmenting therapeutic efficacy of IR against GICs. In addition, our results support further development of clinical trials with PARPi and radiation in glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24121277      PMCID: PMC3890948          DOI: 10.1038/cdd.2013.136

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  53 in total

1.  Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage.

Authors:  E Raderschall; E I Golub; T Haaf
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

Authors:  Shideng Bao; Qiulian Wu; Sith Sathornsumetee; Yueling Hao; Zhizhong Li; Anita B Hjelmeland; Qing Shi; Roger E McLendon; Darell D Bigner; Jeremy N Rich
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

Review 3.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

4.  The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts.

Authors:  L R Kelland; K S Tonkin
Journal:  Radiother Oncol       Date:  1989-08       Impact factor: 6.280

5.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

6.  Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.

Authors:  David Martin-Oliva; Rocío Aguilar-Quesada; Francisco O'valle; Jose Antonio Muñoz-Gámez; Rubén Martínez-Romero; Raimundo García Del Moral; José Mariano Ruiz de Almodóvar; Raquel Villuendas; Miguel Angel Piris; F Javier Oliver
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

7.  Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Authors:  Lenka Oplustilova; Kamila Wolanin; Martin Mistrik; Gabriela Korinkova; Dana Simkova; Jan Bouchal; Rene Lenobel; Jirina Bartkova; Alan Lau; Mark J O'Connor; Jiri Lukas; Jiri Bartek
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

8.  PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation.

Authors:  Anthony Chalmers; Peter Johnston; Mick Woodcock; Michael Joiner; Brian Marples
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

9.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more
  78 in total

Review 1.  Patient-Derived Xenografts as a Model System for Radiation Research.

Authors:  Christopher D Willey; Ashley N Gilbert; Joshua C Anderson; George Yancey Gillespie
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

Review 2.  Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.

Authors:  Yanxin Lu; Yang Liu; Ying Pang; Karel Pacak; Chunzhang Yang
Journal:  Pharmacol Ther       Date:  2018-04-03       Impact factor: 12.310

3.  Radiosensitization of cancer stem cells in glioblastoma by the simultaneous inhibition of parallel DNA damage response pathways.

Authors:  Yasunori Fukumoto
Journal:  Ann Transl Med       Date:  2017-05

Review 4.  Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.

Authors:  Meredith A Morgan; Christine E Canman
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

5.  Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

Authors:  Josephine Kam Tai Dermawan; Masahiro Hitomi; Daniel J Silver; Qiulian Wu; Poorva Sandlesh; Andrew E Sloan; Andrei A Purmal; Katerina V Gurova; Jeremy N Rich; Justin D Lathia; George R Stark; Monica Venere
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

6.  Purine synthesis promotes maintenance of brain tumor initiating cells in glioma.

Authors:  Xiuxing Wang; Kailin Yang; Qi Xie; Qiulian Wu; Stephen C Mack; Yu Shi; Leo J Y Kim; Briana C Prager; William A Flavahan; Xiaojing Liu; Meromit Singer; Christopher G Hubert; Tyler E Miller; Wenchao Zhou; Zhi Huang; Xiaoguang Fang; Aviv Regev; Mario L Suvà; Tae Hyun Hwang; Jason W Locasale; Shideng Bao; Jeremy N Rich
Journal:  Nat Neurosci       Date:  2017-03-27       Impact factor: 24.884

Review 7.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 8.  The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences.

Authors:  Estelle Willems; Arnaud Lombard; Matthias Dedobbeleer; Nicolas Goffart; Bernard Rogister
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

9.  Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.

Authors:  Amanda R King; Christopher D Corso; Evan M Chen; Eric Song; Paul Bongiorni; Zhe Chen; Ranjini K Sundaram; Ranjit S Bindra; W Mark Saltzman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

Review 10.  The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells.

Authors:  Catherine J Libby; Anh Nhat Tran; Sarah E Scott; Corinne Griguer; Anita B Hjelmeland
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.